Beta Bionics (BBNX) vs Sight Sciences (SGHT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Sight Sciences (SGHT) has outperformed Beta Bionics (BBNX) over the past year, gaining 40.2% versus a loss of 57.5%. Beta Bionics is the larger company by market cap ($726.3 million vs $565.8 million), about 1.3 times the size. Sight Sciences converts more of its revenue into profit, with a net margin of -49.7% versus -73.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBNX | SGHT |
|---|---|---|
| Share price | $13.36 | $10.18 |
| Market cap | $726.34M | $565.79M |
| 1-day change | +0.30% | -4.14% |
| YTD return | -56.15% | +28.37% |
| 1-year return | -57.48% | +40.22% |
| 5-year return | — | -46.67% |
| EPS (TTM) | $-1.83 | $-0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $100.25M | $77.36M |
| Revenue growth (YoY) | +53.94% | -3.13% |
| Net income (latest FY) | $-73.20M | $-38.43M |
| Gross margin | 55.40% | 86.17% |
| Operating margin | -71.50% | -47.95% |
| Net margin | -73.02% | -49.67% |
| 52-week high | $32.71 | $11.60 |
| 52-week low | $8.80 | $3.38 |
| Distance from 52-week high | -59.16% | -12.20% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +87.87% | +20.33% |
| Average volume | 1.21M | 313.51K |
| Shares outstanding | 54.37M | 55.58M |
| Employees | 420 | 186 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SGHT has outperformed BBNX by 97.7 percentage points over the past year.
- Sight Sciences is more profitable, keeping -49.7 cents of every revenue dollar as net income versus -73.0 cents for Beta Bionics.
- Beta Bionics grew revenue faster in its latest fiscal year (+53.94% vs -3.13%).
About Beta Bionics
BBNX stock →Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older.
Health Care · Medical/Dental Instruments · 420 employees
About Sight Sciences
SGHT stock →Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye.
Health Care · Medical/Dental Instruments · 186 employees
BBNX vs SGHT FAQ
Which is bigger, Beta Bionics or Sight Sciences?
Beta Bionics (BBNX) is larger, with a market capitalization of $726.34M compared with $565.79M for Sight Sciences (SGHT).
Which stock has performed better over the past year, BBNX or SGHT?
SGHT returned +40.22% over the past 12 months, compared with -57.48% for BBNX (price return, excluding dividends). Past performance does not predict future results.
Are Beta Bionics and Sight Sciences in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.